Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Total Current Liabilities data on record, last reported at $6.0 million in Q1 2025.

  • For Q1 2025, Total Current Liabilities fell 32.46% year-over-year to $6.0 million; the TTM value through Mar 2025 reached $6.0 million, down 32.46%, while the annual FY2025 figure was $6.0 million, 32.46% down from the prior year.
  • Total Current Liabilities reached $6.0 million in Q1 2025 per SXTC's latest filing, down from $8.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.6 million in Q1 2021 and bottomed at $6.0 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $13.0 million, with a median of $14.5 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 51.5% in 2021, then plummeted 38.59% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $18.6 million in 2021, then fell by 7.85% to $17.1 million in 2022, then decreased by 15.33% to $14.5 million in 2023, then tumbled by 38.59% to $8.9 million in 2024, then crashed by 32.46% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $6.0 million in Q1 2025, $8.9 million in Q1 2024, and $14.5 million in Q1 2023.